Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21357

Pharmacology Biochemistry and Behavior

Volumn 54, Issue 2, 1996, Pages 509-516

  Griebel, Guy ^a,e   Blanchard, D Caroline ^a,b   Rettori, Marie Claire ^d   Guardiola Lemaître, Béatrice ^d   Blanchard, Robert J ^a,c  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^e SANOFI   (France)

Author keywords

5 HT1A receptor; Antipredator defense; Anxiety; Flight; Head twitch; Mixed 5 HT1A 5 HT2A antagonist; Panic; Predator assessment; S 21357; Serotonin

Indexed keywords

3 [2 [4 (4 FLUOROBENZOYL)PIPERIDINO]ETHYL] 6 [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BENZOTHIAZOLIN 2 ONE; LESOPITRON; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PANIC; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SEROTONINERGIC SYSTEM;

ADENYLATE CYCLASE; ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION; THIAZOLES;

ANIMALIA;

EID: 0029984817     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02215-5     Document Type: Article

References (47)

1. 2A receptors. Eur. J. Pharmacol. 261:285-294; 1994.
2. Arriaga, F.; Leitao, J.; Padua, J.; Ruiz, I.; Tropa, J.; Sousa, M. P.; Mills, F. J.; Gelders, Y. Ritanserin, an original sleep quality improving agent in generalized anxiety disorders. C.I.N.P. Congress, Puerto Rico; 1986:174.
3. Barrett, J. E.; Vanover, K. E. 5-HT receptors as targets for the development of novel anxiolytic drugs: Models, mechanisms and future directions. Psychopharmacology (Berlin) 112:1-12; 1993.
4. 2 antagonist WY-50324 in pigeons. Drug Dev. Res. 24:179-188; 1991.
5. Blanchard, R. J.; Yudko, E. B.; Rodgers, R. J.; Blanchard, D. C. Defense system psychopharmacology: An ethological approach to the pharmacology of fear and anxiety. Behav. Brain Res. 58:155-165; 1993.
6. 1A receptors negatively coupled with adenylate cyclase in hippocampal neurons. Naunyn Schmiedebergs Arch. Pharmacol. 335:588-592; 1987.
7. Boyer, W. F.; Feighner, J. P. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone vs. diazepam in generalized anxiety disorder. Int. Clin. Psychopharmacol. 8:173-176; 1993.
8. Ceulemans, D. L.; Hoppenbrouwers, M. L.; Gelders, Y. G.; Reyntjens, A. J. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: A double-blind placebo-controlled study vs. lorazepam. Pharmacopsychiatry 18:303-305; 1985.
9. Chignon, J. M.; Lepine, E. P. Panic and hypertension associated with a single dose of buspirone. Lancet 11:46-47; 1989.
10. 1A agonist and potential anxiolytic agent. Drug Dev. Res. 26:21-48; 1992.
11. Cutler, N. R.; Sramek, J. J.; Keppel Hesselink, J. M.; Krol, A.; Roeschen, J.; Rickels, K.; Schweizer, E. A double-blind, placebocontrolled study comparing the efficacy and safety of ipsapirone vs. lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial. J. Clin. Psychopharmacol. 13:429-437; 1993.
12. 2 receptor sensitivity in generalised anxiety disorder: A pilot study with ritanserin. Psychopharmacology (Berlin) 108:387-389; 1992.
13. DSM-IV diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
14. 1A receptor antagonists: Utility as research tools and therapeutic agents. Trends Pharmacol. Sci. 14:41-48; 1993.
15. Frazer, G. A.; Lapierre, Y. D. The effect of buspirone on panic disorder: A case report [letter]. J. Clin. Psychopharmacol. 7:118-119; 1987.
16. Goldberg, H. L.; Finnerty, R. Comparison of buspirone in two separate studies. J. Clin. Psychiatry 43:87-91; 1982.
17. Graeff, F. G. Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: Briley, M.; File, S. E., eds. New concepts in anxiety. New York: CRC Press; 1991:288-307.
18. Griebel, G.; Blanchard, D. C.; Agnes, R. S.; Blanchard, R. J. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berlin) 120: 57-66; 1995.
19. Griebel, G.; Blanchard, D. C.; Jung, A.; Blanchard, R. J. A model of "antipredator" defense in Swiss-Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities. Behav. Pharmacol. 6:732-745; 1995.
20. Griebel, G.; Blanchard, D. C.; Jung, A.; Lee, J. C.; Masuda, C. K.; Blanchard, R. J. Further evidence that the Mouse Defense Test Battery is useful for screening anxiolytic and panicolytic drugs: Effects of acute and chronic treatment with alprazolam. Neuropharm. 34:1625-1633; 1995.
21. 2A antagonist pirenperone. Pharmacol. Biochem. Behav. 51:235-244; 1995.
22. Griebel, G.; Blanchard, D. C.; Blanchard, R. J. Predator-elicited flight responses in Swiss-Webster mice: An experimental model of panic attacks. Prog. Neuro-Psychopharmacol. Biol. Psychiat. (in press).
23. 1A receptors: In vitro and in vivo studies in the rat. Eur. J. Pharmacol. 255:185-196; 1994.
24. 1A autoreceptor interactions in the rat dorsal raphé nucleus: An in vitro electrophysiological study. Neuroscience 41:495-505; 1991.
25. 1A agonists with potential anxiolytic properties. J. Pharmacol. Exp. Ther. 246:745-752; 1988.
26. Hendrie, C. A.; Neill, J. C. An animal model of panic disorder. J. Psychopharmacol. 6:125; 1991.
27. 2 receptor antagonist) in panic disorder and agoraphobia. Clinical and biochemical effects. C.I.N.P. Congress, Puerto Rico; 165:1986.
28. 1C) receptors on periaqueductal gray aversion. Eur. J. Pharmacol. 161:219-221; 1989.
29. 3 receptors. Psychopharmacology (Berlin) 97:489-495; 1989.
30. 1A receptors in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 347:453-463; 1993.
31. 1A receptors. J. Pharmacol. Exp. Ther. 264:863-872; 1993.
32. 1A receptor ligands (+)-WAY 100135 and SDZ 216-525. Eur. J. Pharmacol. 249:25-35; 1993.
33. 1C/2 antagonists, potential anxiolytic agents. In: Hamon, M.; Ollat, H.; Thiebot, M. H., eds. Anxiety: Neurobiology, clinic and therapeutic perspectives. Paris: Les editions INSERM/ John Libbey Eurotext; 1993:153-164.
34. 1A agonist of high efficacy and exceptional in vivo potency. Eur. J. Pharmacol. 203:319-322; 1991.
35. Munjack, D. J.; Bruns, J.; Baltazar, P. L.; Brown, R. A pilot study of buspirone in the treatment of social phobia. J. Anxiety Disord. 5:87-98; 1991.
36. Norman, T. R.; Judd, F. K. Panic attacks, buspirone, and serotonin function. Lancet 11:15; 1989.
37. Ortmann, R.; Martin, S.; Radeke, E.; Delini Stula, A. Interaction of beta-adrenoceptor agonists with the serotonergic system in rat brain. A behavioral study using the L-5-HTP syndrome. Naunyn Schmiedebergs Arch. Pharmacol. 316:225-230; 1981.
38. Pohl, R.; Balon, R.; Yeragani, V. K.; Gershon, S. Serotonergic anxiolytics in the treatment of panic disorder: A controlled study with buspirone. Psychopathology 22(Suppl. 1):60-67; 1989.
39. Rettori, M. C.; Caignard, D. H.; Renard, P.; Griebel, G.; Blanchard, R. J.; Guardiola-Lemaître, B. Antipanic-like activity of S 21357-1 in mice. Soc. Neurosci. Abstr. 20:1774; 1994.
40. Rickels, K.; Weisman, K.; Norstad, N.; Singer, M.; Stoltz, D.; Brown, A.; Danton, J. Buspirone and diazepam in anxiety: A controlled study. J. Clin. Psychiatry 43:81-86; 1982.
41. Sano, K.; Sekino, H.; Mayanagi, Y. Results of stimulation and destruction of posterior hippocampus in cases with violent, aggressive and restless behaviors. In: Hitchcoch, E.; Laitinen, L.; Vaernet, K., eds. Psychosurgery. Springfield, IL: Thomas; 1972:57.
42. Schneier, F. R.; Saoud, J. B.; Campeas, R.; Fallon, B. A.; Hollander, E.; Coplan, J.; Liebowitz, M. R. Buspirone in social phobia. J. Clin. Psychopharmacol. 13:251-256; 1993.
43. Sheehan, D. V.; Raj, A. B.; Harnett Sheehan, K.; Soto, S. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: A double-blind placebo-controlled study. Acta Psychiatr. Scand. 88:1-11; 1993.
44. Sheehan, D. V.; Raj, A. B.; Sheehan, K. H.; Soto, S. Is buspirone effective for panic disorder? J. Clin. Psychopharmacol. 10: 3-11; 1990.
45. Vandermaelen, C. P.; Aghajanian, G. K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 289:109-115; 1983.
46. Westenberg, H. G. M.; Den Boer, J. A. Serotonin in anxiety related disorders. In: Vanhoutte, P. M.; Saxena, P. R.; Paoletti, R.; Brunello, N.; Jackson, A. S., eds. Serotonin, from cell biology to pharmacology and therapeutics. Dordrecht: Kluwer Academic Publishers; 1993:249-254.
47. 2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat. Neuropharmacology 22:801-804; 1983.